ACOG earnings analysis
What we found in ACOG's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Q2 2026 revenue of $6.092 million increased approximately 52% sequentially and 205% year over year, and exceeded consensus by approximately 6%, while diluted EPS of negative $0.40 deteriorated sequentially but improved year over year. Free cash flow remained negative at $6 million, and the company disclosed that all prior financing proceeds had been utilized as of June 30, 2026. The most material concern is that disclosure controls remained ineffective because the previously identified material weakness had not yet been remediated.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Accelerated and Beat Estimates
- Q2 2026 revenue was $6.092 million, up approximately 52% from $4 million in Q1 2026 and approximately 205% from $2 million in Q2 2025. Revenue also exceeded the $5.750 million consensus estimate by approximately 6%.
- EPS Improved Year Over Year
- Diluted EPS was negative $0.40 versus negative $0.32 in Q1 2026, a deterioration of $0.08 sequentially, but improved by $0.25 from negative $0.65 in Q2 2025.
- Free Cash Flow Burn Improved Sequentially
- Free cash flow was negative $6 million in Q2 2026, improving from negative $12 million in Q1 2026 and matching the negative $6 million reported in Q2 2025.
- Material-Weakness Remediation Underway
- The company implemented additional management review controls over reconciliations, variance analyses, and journal-entry approvals during the six months ended June 30, 2026, and engaged external technical accounting specialists.
- Commercialization Investment Continued
- The company spent approximately $29.32 million of financing proceeds on commercialization and launch efforts for ZUNVEYL, formerly ALPHA-1062, in Alzheimer’s disease.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material Weakness Remains Unremediated
- Disclosure controls and procedures were not effective as of June 30, 2026 because the previously identified material weakness had not operated for a sufficient period to demonstrate remediation. The weakness includes accounting for warrants and stock-option liabilities, deferred-tax disclosures, and inadequate segregation of duties.
- Financing Proceeds Fully Utilized
- The company stated that it had utilized all proceeds from prior financings as of June 30, 2026. Of approximately $46.15 million in net proceeds, cumulative uses included $29.32 million for ZUNVEYL commercialization, $4.13 million for commercial CMC activities, and $11.50 million for working capital and general corporate purposes.
- Ongoing Losses and Cash Burn
- The company continues to report substantial cash consumption: free cash flow was negative $6 million in Q2 2026, following negative $12 million in Q1 2026. Continued commercialization spending alongside negative EPS of $0.40 increases dependence on future operating cash generation or external financing.
- Current Margin Disclosure Incomplete
- Gross margin was 67.8% in Q2 2025 and operating margin was negative 346.1% in Q2 2025; current-quarter margin figures were not available in the provided filing text, limiting assessment of the profitability trend.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.4
What they said about what is next.
No quantitative revenue or EPS guidance was identified in the provided 10-Q text. The filing states that all proceeds from prior financings had been utilized as of June 30, 2026.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Alpha Cognition Inc. reported total revenues of $3,533,798 for Q1 2026, marking a 21% increase from $2,928,654 in Q1 2025, driven by significant growth in commercial sales of ZUNVEYL. However, net loss widened to…
- 10-K · March 31, 2026
- Alpha Cognition commercially launched ZUNVEYL following FDA approval on July 26, 2024 and an official U.S. launch on March 19, 2025, pursuing a long‑term care (LTC) focused commercialization strategy and international…
- 10-Q · November 13, 2025
- Alpha Cognition reported Q3 revenue of $2,840,858 driven by product sales ($2,334,222) and licensing ($506,636), producing a meaningful sequential and year-over-year revenue increase. Diluted loss per share improved to…
- 10-Q · August 14, 2025
- Alpha Cognition reported its first commercial revenue in Q2 2025 with total revenue of $1,657,687, driven by product sales of $1,576,411 and licensing revenue of $81,276. Despite revenue generation, the company posted a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ACOG makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever